以质量求发展,以服务铸品牌

Journal of Nursing ›› 2021, Vol. 28 ›› Issue (10): 67-69.doi: 10.16460/j.issn1008-9969.2021.10.067

Previous Articles     Next Articles

  

  • Received:2020-08-26 Online:2021-05-25 Published:2021-06-09

CLC Number: 

  • R473.73
[1] 石远凯,孙燕,于金明,等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.DOI:10.3779/j.issn.1009-3419.2016.01.01.
[2] 赫捷. 中国胸外科的现状和未来发展[J].中华医学信息导报,2015,30(22):12.
[3] Massarelli E, Papadimitrakopoulou V, Welsh J, et al.Immunotherapy in Lung Cancer[J]. Transl Lung Cancer Res,2014,3(1):53-63.
[4] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M].北京:人民卫生出版社,2019:17-23.
[5] Sibaud V.Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy[J]. AmJClin Dermatol, 2018, 19(3):345-361. DOI: 10.1007/s40257-017-0336-3.
[6] Haanen J, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy:Esmo Clinical Practice Guidelines for Diagnosis,Treatment and Follow-up[J]. Annals of Oncology:Official Journal of the European Society for Medical Oncology,2017,28(suppl_4):iv119-iv142.
[7] 张婷婷,张丽燕,国仁秀.PD-1抑制剂治疗消化道肿瘤中免疫相关不良事件的护理[J].肿瘤综合治疗电子杂志,2019,5(1):111-114.DOI:10.12151/JMCM.2019.01-13.
[8] 王艳,何瑞仙,翟敏峰,等. 程序性死亡蛋白1抑制剂引起免疫相关性皮肤毒性的护理[J].中华现代护理志,2020,26(25):3526-3529.DOI:10.3760/cma.j.cn115682-10191227-04801.
[9] Gettinger S,Horn L,Jackman D,et al.Five-year Follow-up of Nivolumab in Previously Treated Advanced Non-small-cell Lung Cancer: Results From the CA209-003 Study[J].J Clin Oncol,2018,36(17):1675-1684.
[10] Angell TE, Min L, Wieczorek TJ, et al.Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma[J]. Genes Diseases, 2017,5(1):46-48.
[11] Maekura T, Naito M, Tahara M, et al.Predictive Factors of Niv-olumab-induced Hypothyroidism in Patients with Non-Small Cell Lung Cancer[J].In Vivo,2017,31(5):1035-1039.
[12] 何瑞仙,王艳,苏伟才,等.铂类化疗药物治疗肺癌患者症状簇的调查研究[J].中国肿瘤临床与康复,2019,26(1):9-13. DOI:10.13455/j.cnki.cjcor.2019.01.03.
[13] 斯晓燕,何春霞,张丽,等.免疫检查点抑制剂相关皮肤不良反应诊治建议[J].中国肺癌杂志,2019,22(10):639-644. DOI:10.3779/j.issn.1009-3419.2019.10.06.
[14] Naidoo J, Wang X, Woo KM, et al.Pneumonitis In Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy[J].J Clin Ooncol,2017,35(7):709-717.
[15] 薛静,张丽燕.消化道肿瘤患者免疫检查点抑制剂治疗所致不良反应的护理[J].护理学报,2019,26(13):63-65. DOI:10.16460/j.issn1008-9969.2019.13.063.
[16] 付恩锋,王艳,王洁.70例非小细胞肺癌患者免疫检查点抑制剂不良反应分析及护理对策[J].护理学报,2020,27(14):68-70. DOI:10.16460/j.issn1008-9969.2020.14.068.
[17] Champiat S, Lambotte O, Barreau E, et al.Management of Immune Checkpoint Blockade Dysimmune Toxicities:A Collaborative Position Paper[J].Ann Oncol,2016,27(4):559-574.
[1] CAO Min, ZHANG Pei-li, HOU Xiao-ya, GAO Chao-yue, GUO Lin-fang, LI Ying. Nutritional care experience of caregivers of colorectal cancer patients undergoing chemotherapy based on ABC-X model: a qualitative study [J]. Journal of Nursing, 2025, 32(2): 13-18.
[2] LIU Qi, LIU Jia-li, LIU Yu, YANG Li-min, FAN Yu-ying, LV Xing, JIN Hui-ying. Physical-psychological symptom burden trajectories and influencing factors in nasopharyngeal carcinoma patients during induction chemotherapy plus concurrent chemoradiotherapy [J]. Journal of Nursing, 2025, 32(1): 1-6.
[3] . [J]. Journal of Nursing, 2025, 32(1): 39-43.
[4] YAO Wan-qing, YANG Li-zhuang, CHEN Dan-dan, ZHANG Wan-qiu, LU Wei, GUAN Cui-hong, LI Hai. Efficacy of different non-drug interventions on cancer-related fatigue in breast cancer patients: a network Meta-analysis [J]. Journal of Nursing, 2024, 31(24): 37-43.
[5] DAI Qian, LIU Xiang-yu, ZHU Xiao-mei, WANG Jia-li, HUANG Yuan-si. Status quo of self-compassion in patients with colorectal cancer stoma and its influencing factors [J]. Journal of Nursing, 2024, 31(23): 13-17.
[6] . [J]. Journal of Nursing, 2024, 31(22): 73-78.
[7] LI Yue-ge, KONG Han, CAO Ding, LI Jia-xin, SHANG Ya-meng, CHANG Shu-ying. Current status of fear of cancer recurrence in young and middle-aged patients with cervical cancer after surgery and its influencing factors: a 228-case study [J]. Journal of Nursing, 2024, 31(20): 8-12.
[8] . [J]. Journal of Nursing, 2024, 31(20): 19-23.
[9] . [J]. Journal of Nursing, 2024, 31(20): 29-32.
[10] . [J]. Journal of Nursing, 2024, 31(18): 30-34.
[11] GENG Yu-fang, QIN Ru-meng, WANG Hui, ZHANG Shan-shan, ZHOU Li-hua. Construction of post-traumatic growth model of ovarian cancer patients based on interpretative phenomenological analysis [J]. Journal of Nursing, 2024, 31(18): 73-78.
[12] . [J]. Journal of Nursing, 2024, 31(17): 51-56.
[13] YU Feng, SUN Li, HU De-ying, HU Jie, WANG Jia-qing, LV Chu-feng. Competency model of suicide gatekeeper for oncology nurses based on behavioral event interview and expert consultation [J]. Journal of Nursing, 2024, 31(17): 73-78.
[14] . [J]. Journal of Nursing, 2024, 31(16): 56-61.
[15] ZHANG Shu-zhen, YU Wen-ru, ZHANG Jun-feng, JIANG Jia-yao, LUO Mei, LIN Bi-yu, MAI Min-wen, YANG Meng-ting. Evidence-based nursing practice in prevention and management of radiation dermatitis in cancer patients undergoing radiotherapy [J]. Journal of Nursing, 2024, 31(16): 62-66.
Viewed
Full text


Abstract

Cited

  Shared   
No Suggested Reading articles found!